Waverly Advisors LLC Has $2.77 Million Holdings in Becton, Dickinson and Company $BDX

Waverly Advisors LLC lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 108.2% in the 1st quarter, Holdings Channel reports. The institutional investor owned 17,640 shares of the medical instruments supplier’s stock after acquiring an additional 9,166 shares during the period. Waverly Advisors LLC’s holdings in Becton, Dickinson and Company were worth $2,774,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in Becton, Dickinson and Company by 57.8% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 17,884 shares of the medical instruments supplier’s stock worth $2,812,000 after acquiring an additional 6,554 shares during the period. Dai ichi Life Insurance Company Ltd boosted its position in shares of Becton, Dickinson and Company by 7.7% in the 1st quarter. Dai ichi Life Insurance Company Ltd now owns 25,159 shares of the medical instruments supplier’s stock worth $3,956,000 after purchasing an additional 1,796 shares during the last quarter. Gabelli Funds LLC boosted its position in shares of Becton, Dickinson and Company by 6.1% in the 1st quarter. Gabelli Funds LLC now owns 47,003 shares of the medical instruments supplier’s stock worth $7,390,000 after purchasing an additional 2,708 shares during the last quarter. Hilltop Holdings Inc. acquired a new stake in shares of Becton, Dickinson and Company during the first quarter worth $277,000. Finally, Morningstar Investment Management LLC increased its holdings in Becton, Dickinson and Company by 5.3% in the first quarter. Morningstar Investment Management LLC now owns 19,364 shares of the medical instruments supplier’s stock valued at $3,045,000 after purchasing an additional 983 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,189 shares of company stock valued at $765,661 over the last quarter. 0.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Stock Performance

BDX opened at $168.56 on Thursday. The business’s 50-day simple moving average is $151.10 and its 200 day simple moving average is $163.89. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. The firm has a market capitalization of $46.44 billion, a PE ratio of 42.67, a PEG ratio of 11.77 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business’s revenue was up 5.2% compared to the same quarter last year. During the same period last year, the company earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 12.62 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be paid a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.5%. Becton, Dickinson and Company’s dividend payout ratio is currently 106.33%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on BDX shares. Royal Bank Of Canada set a $175.00 target price on Becton, Dickinson and Company in a research report on Tuesday, April 14th. The Goldman Sachs Group decreased their price objective on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a report on Wednesday, May 27th. Weiss Ratings lowered shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Finally, Bank of America lowered their price objective on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $180.93.

More Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: UBS initiated coverage with a Buy rating and a $190 price target, implying meaningful upside from recent trading levels. The upgrade may be the biggest near-term catalyst, signaling that UBS sees improving risk-reward prospects for BD. UBS initiates coverage of Becton Dickinson
• Positive Sentiment: BD and Brazilian pharmaceutical company EMS launched a semaglutide product in Brazil, combining EMS’s pharmaceutical capabilities with BD’s advanced drug-delivery technology. The partnership could expand access to GLP-1 therapies and create potential demand for BD’s injection and delivery systems. EMS and BD semaglutide launch
• Neutral Sentiment: BD declared a quarterly dividend of $1.05 per share, payable September 30 to shareholders of record September 9. The announcement supports the company’s shareholder-return profile, although the dividend was expected and is unlikely to materially change earnings expectations. BD dividend announcement
• Negative Sentiment: Executive Vice President Michael Feld sold 75 shares worth approximately $11,785 under a pre-arranged Rule 10b5-1 trading plan. Because the sale reduced his holdings by only 0.36% and was scheduled in advance, it represents a limited negative signal rather than a major change in insider sentiment. BDX insider stock sale

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.